Robert E Conway, a director of Nivalis Therapeutics, Inc., recently acquired 20,000 shares of the company. The buys took place at $2.30 per share, on May 05, 2017. Conway now owns 40,000 shares of the company. Conway operates out of Boulder, CO. Some additional info was provided as follows:
The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.262 to $2.338, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Securities to be offered to employees in employee benefit plans - June 21, 2018
Departure of Directors or Certain - June 14, 2018
Nivalis Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - June 11, 2018
Entry into a Material Definitive - June 11, 2018